Staack, R. F.; Theobald, D. S.; Paul, L. D.; Springer, D.; Kraemer, T.; Maurer, H. H. published an article about the compound: 4-(Piperazin-1-yl)phenol( cas:56621-48-8,SMILESS:OC1=CC=C(N2CCNCC2)C=C1 ).SDS of cas: 56621-48-8. Aromatic heterocyclic compounds can be classified according to the number of heteroatoms or the size of the ring. The authors also want to convey more information about this compound (cas:56621-48-8) through the article.
The in vivo metabolism of 1-(4-methoxyphenyl)piperazine (MeOPP), a novel designer drug, was studied in male Wistar rats. MeOPP was mainly O-demethylated to 1-(4-hydroxyphenyl)piperazine (4-HO-PP) in addition to degradation of the piperazine moiety. O-demethylation, the major metabolic step, was studied with cDNA-expressed human hepatic cytochrome P 450 (CYP) enzymes in pooled human liver microsomes (pHLM) and in single donor human liver microsomes with CYP2D6 poor metabolizer genotype (PM HLM). CYP2D6 catalyzed O-demethylation with apparent Km and Vmax values of 48.34 μM and 5.44 pmol min-1 pmol-1 CYP, resp. pHLM catalyzed the monitored reaction with an apparent Km = 204.80 μM and Vmax = 127.50 pmol min-1 mg-1 protein. The CYP2D6-specific chem. inhibitor quinidine (1 and 3 μM) significantly inhibited 4-HO-PP formation by 71.9% and by 98.5%, resp., in incubation mixtures with pHLM and 200 μM MeOPP. O-demethylation was significantly lower in PM HLM compared with pHLM (70.6%). These data suggest that polymorphically expressed CYP2D6 is the enzyme mainly responsible for MeOPP O-demethylation.
In some applications, this compound(56621-48-8)SDS of cas: 56621-48-8 is unique.If you want to know more details about this compound, you can contact with the author or consult more relevant literature.
Reference:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem